Editorial p1313 Alzheimer's disease: are health systems ready? The Lancet + +... + +

Minimum effective low dose of antithymocyte globulin in people aged 5–25 years with recent-onset stage 3 type 1 diabetes (MELD-ATG): a phase 2, multicentre, double-blind, randomised, placebo-controlled, adaptive dose-ranging trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01674-5/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_easd25&_hsenc=p2ANqtz-9IfOZivVoVHNjCDEAqYSvNcZvUT7rxu8VxDF8o2jcPPvFAExWs7WUkMYBJNcvJp_URmYcWgUHOx9Mq945ECLrA5HUysg&_hsmi=380999764&utm_content=380999764&utm_source=hs_email Editorial p1313 Alzheimer's disease: are health systems ready? The Lancet https://www.thelancet.com/journals/lancet/issue/vol406no10510/PIIS0140-6736(25)X0039-8 Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01774-X/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_easd25&_hsenc=p2ANqtz--gyptOL7plzIOKloLxVIQ6570RPyvxVA2d1fZbE37Ww2U6j-S4NMhyO5_T6zfiFjXnnAG2-6oUBmGuTr6Tv4B8bsZbNw&_hsmi=380999764&utm_content=380999764&utm_source=hs_email ATG as disease-modifying therapy for new-onset type 1 diabetes https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01773-8/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_easd25&_hsenc=p2ANqtz-_osuH1TFREfd7X9Klr2q4U0oifDnt4yFgGmaWFraBZMDIBBpF8KHUkV4A6hemIY9QKuFtr-hzT0s13sHrIMhxi4LClSw&_hsmi=380999764&utm_content=380999764&utm_source=hs_email